Objective:

To announce the FDA approval of zilganersen (Zanvastro) for treating Alexander disease.

Approach:

• FDA Approval: The FDA approved zilganersen injection for pediatric and adult patients with Alexander disease.
• Disease Overview: Alexander disease is a rare neurologic condition caused by mutations affecting GFAP production, leading to nervous system damage.
• Treatment Mechanism: Zilganersen is an antisense oligonucleotide that limits the production and accumulation of abnormal GFAP.
• Clinical Study: The FDA evaluated zilganersen's efficacy and safety in a multicenter, randomized, controlled study of 49 patients aged 2 years and older.
• Efficacy Results: At 61 weeks, patients aged 5 years and older showed significantly better walking speed with zilganersen compared to no treatment.
• Motor Assessment: Younger patients (aged 2 to 4 years) showed improvement on a broader motor assessment, while the control group declined.
• Safety Findings: The most common adverse reactions included vomiting, back pain, cough, headache, and post-lumbar puncture syndrome.

Key Findings:

• Zilganersen is the first approved therapy for Alexander disease.
• The drug is administered every 3 months via spinal canal injection.
• Clinical trial data supported the inclusion of patients younger than 2 years in the approved indication.

Limitations:

• Limited clinical trial data for patients younger than 2 years due to the rarity of the disease.
• Lack of a concurrent control group for younger patients.

Sources:

• US Food and Drug Administration